Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(N/A%)
USD 0.15
(N/A%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.89 Million USD | 0.0% |
| 2022 | -2.89 Million USD | 43.78% |
| 2021 | -5.14 Million USD | -51.73% |
| 2020 | -3.39 Million USD | 75.32% |
| 2019 | -13.73 Million USD | -53.72% |
| 2018 | -8.93 Million USD | 11.89% |
| 2017 | -10.14 Million USD | -36.4% |
| 2016 | -7.43 Million USD | -92.83% |
| 2015 | -3.85 Million USD | 66.45% |
| 2014 | -11.49 Million USD | -87.31% |
| 2013 | -6.13 Million USD | -25.75% |
| 2012 | -4.88 Million USD | 15.29% |
| 2011 | -5.76 Million USD | 0.0% |
| 2009 | -12.94 Million USD | 55.0% |
| 2008 | -28.76 Million USD | 50.52% |
| 2007 | -58.13 Million USD | 27.03% |
| 2006 | -79.66 Million USD | -26.89% |
| 2005 | -62.78 Million USD | -155.09% |
| 2004 | -24.61 Million USD | -97.45% |
| 2003 | -12.46 Million USD | -36.27% |
| 2002 | -9.14 Million USD | -40.98% |
| 2001 | -6.48 Million USD | -20.09% |
| 2000 | -5.4 Million USD | -12.75% |
| 1999 | -4.79 Million USD | 12.57% |
| 1998 | -5.48 Million USD | -57.15% |
| 1997 | -3.48 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -355.73 Thousand USD | 59.33% |
| 2024 Q3 | -1.88 Million USD | -3390.75% |
| 2024 Q2 | -54.12 Thousand USD | 84.79% |
| 2023 FY | -2.89 Million USD | 0.0% |
| 2023 Q3 | -296.04 Thousand USD | 68.8% |
| 2023 Q4 | -874.72 Thousand USD | -195.47% |
| 2023 Q1 | -766.78 Thousand USD | 68.67% |
| 2023 Q2 | -948.71 Thousand USD | -23.73% |
| 2022 FY | -2.89 Million USD | 43.78% |
| 2022 Q1 | -924.56 Thousand USD | 43.0% |
| 2022 Q2 | -1 Million USD | -8.18% |
| 2022 Q3 | -1.23 Million USD | -23.21% |
| 2022 Q4 | -2.44 Million USD | -98.57% |
| 2021 Q2 | -1.04 Million USD | 40.0% |
| 2021 Q4 | -1.62 Million USD | -257.95% |
| 2021 Q1 | -1.74 Million USD | -31.08% |
| 2021 FY | -5.14 Million USD | -51.73% |
| 2021 Q3 | 1.02 Million USD | 197.95% |
| 2020 Q2 | -2.07 Million USD | 35.72% |
| 2020 Q3 | -1.45 Million USD | 29.84% |
| 2020 Q4 | -1.33 Million USD | 8.34% |
| 2020 FY | -3.39 Million USD | 75.32% |
| 2020 Q1 | -3.22 Million USD | 14.8% |
| 2019 FY | -13.73 Million USD | -53.72% |
| 2019 Q4 | -3.78 Million USD | 4.29% |
| 2019 Q1 | -3.14 Million USD | -25.43% |
| 2019 Q3 | -3.95 Million USD | -38.29% |
| 2019 Q2 | -2.85 Million USD | 9.22% |
| 2018 FY | -8.93 Million USD | 11.89% |
| 2018 Q1 | -1.99 Million USD | 49.13% |
| 2018 Q3 | -2.55 Million USD | -41.27% |
| 2018 Q2 | -1.8 Million USD | 9.32% |
| 2018 Q4 | -2.51 Million USD | 1.54% |
| 2017 Q1 | -2.12 Million USD | 32.33% |
| 2017 Q2 | -2 Million USD | 5.66% |
| 2017 Q3 | -2.11 Million USD | -5.5% |
| 2017 Q4 | -3.91 Million USD | -85.45% |
| 2017 FY | -10.14 Million USD | -36.4% |
| 2016 FY | -7.43 Million USD | -92.83% |
| 2016 Q1 | -914.66 Thousand USD | 26.66% |
| 2016 Q4 | -3.13 Million USD | -66.49% |
| 2016 Q2 | -1.5 Million USD | -64.79% |
| 2016 Q3 | -1.88 Million USD | -24.84% |
| 2015 Q4 | -1.24 Million USD | 25.34% |
| 2015 FY | -3.85 Million USD | 66.45% |
| 2015 Q3 | -1.67 Million USD | 46.81% |
| 2015 Q2 | -3.14 Million USD | -242.65% |
| 2015 Q1 | 2.2 Million USD | 134.8% |
| 2014 FY | -11.49 Million USD | -87.31% |
| 2014 Q1 | -1.34 Million USD | 3.19% |
| 2014 Q2 | -1.78 Million USD | -32.95% |
| 2014 Q3 | -2.04 Million USD | -14.94% |
| 2014 Q4 | -6.32 Million USD | -208.89% |
| 2013 Q2 | -1.35 Million USD | 29.88% |
| 2013 Q4 | -1.38 Million USD | 5.07% |
| 2013 Q3 | -1.45 Million USD | -7.39% |
| 2013 Q1 | -1.93 Million USD | -50.69% |
| 2013 FY | -6.13 Million USD | -25.75% |
| 2012 Q4 | -1.28 Million USD | -217.14% |
| 2012 Q1 | -2.72 Million USD | -43.07% |
| 2012 FY | -4.88 Million USD | 15.29% |
| 2012 Q3 | 1.09 Million USD | 155.73% |
| 2012 Q2 | -1.96 Million USD | 27.71% |
| 2011 Q4 | -1.9 Million USD | 9.93% |
| 2011 Q2 | -316.44 Thousand USD | 77.83% |
| 2011 Q1 | -1.42 Million USD | 0.0% |
| 2011 FY | -5.76 Million USD | 0.0% |
| 2011 Q3 | -2.11 Million USD | -567.87% |
| 2010 Q3 | -1.05 Million USD | 17.39% |
| 2010 Q2 | -1.27 Million USD | 16.29% |
| 2010 Q1 | -1.52 Million USD | -203.17% |
| 2009 FY | -12.94 Million USD | 55.0% |
| 2009 Q4 | 1.48 Million USD | 160.87% |
| 2009 Q3 | -2.43 Million USD | 67.37% |
| 2009 Q2 | -7.46 Million USD | -37.45% |
| 2009 Q1 | -5.42 Million USD | 25.18% |
| 2008 FY | -28.76 Million USD | 50.52% |
| 2008 Q4 | -7.25 Million USD | -43.34% |
| 2008 Q1 | -6.56 Million USD | 8.5% |
| 2008 Q3 | -5.06 Million USD | 44.16% |
| 2008 Q2 | -9.06 Million USD | -38.17% |
| 2007 Q3 | -13.17 Million USD | 35.34% |
| 2007 Q1 | -16.98 Million USD | 21.13% |
| 2007 FY | -58.13 Million USD | 27.03% |
| 2007 Q4 | -7.16 Million USD | 45.6% |
| 2007 Q2 | -20.37 Million USD | -19.94% |
| 2006 Q1 | -16.12 Million USD | 42.17% |
| 2006 Q4 | -21.54 Million USD | -6.31% |
| 2006 Q3 | -20.26 Million USD | -1.43% |
| 2006 Q2 | -19.97 Million USD | -23.89% |
| 2006 FY | -79.66 Million USD | -26.89% |
| 2005 Q1 | -9.06 Million USD | 18.72% |
| 2005 Q3 | -14.96 Million USD | -44.93% |
| 2005 FY | -62.78 Million USD | -155.09% |
| 2005 Q2 | -10.32 Million USD | -13.92% |
| 2005 Q4 | -27.88 Million USD | -86.32% |
| 2004 Q4 | -11.15 Million USD | -163.01% |
| 2004 Q1 | -3.65 Million USD | -0.39% |
| 2004 Q2 | -5.34 Million USD | -46.09% |
| 2004 Q3 | -4.24 Million USD | 20.65% |
| 2004 FY | -24.61 Million USD | -97.45% |
| 2003 Q2 | -2.93 Million USD | 6.58% |
| 2003 Q1 | -3.13 Million USD | -25.05% |
| 2003 Q4 | -3.64 Million USD | -33.88% |
| 2003 FY | -12.46 Million USD | -36.27% |
| 2003 Q3 | -2.72 Million USD | 7.13% |
| 2002 Q1 | -1.77 Million USD | -1.64% |
| 2002 FY | -9.14 Million USD | -40.98% |
| 2002 Q3 | -2.25 Million USD | 14.74% |
| 2002 Q4 | -2.5 Million USD | -11.2% |
| 2002 Q2 | -2.64 Million USD | -49.24% |
| 2001 FY | -6.48 Million USD | -20.09% |
| 2001 Q4 | -1.74 Million USD | -13.07% |
| 2001 Q3 | -1.54 Million USD | 8.59% |
| 2001 Q2 | -1.68 Million USD | -11.56% |
| 2001 Q1 | -1.51 Million USD | 5.94% |
| 2000 Q1 | -1 Million USD | 36.04% |
| 2000 Q3 | -1.39 Million USD | -7.85% |
| 2000 FY | -5.4 Million USD | -12.75% |
| 2000 Q4 | -1.6 Million USD | -15.03% |
| 2000 Q2 | -1.29 Million USD | -29.5% |
| 1999 Q1 | -1.19 Million USD | 21.5% |
| 1999 Q2 | -1.09 Million USD | 8.04% |
| 1999 Q4 | -1.56 Million USD | -45.51% |
| 1999 Q3 | -1.07 Million USD | 2.07% |
| 1999 FY | -4.79 Million USD | 12.57% |
| 1998 Q2 | -1.45 Million USD | -32.4% |
| 1998 Q3 | -1.43 Million USD | 0.78% |
| 1998 Q1 | -1.09 Million USD | 0.0% |
| 1998 FY | -5.48 Million USD | -57.15% |
| 1998 Q4 | -1.52 Million USD | -5.68% |
| 1997 FY | -3.48 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 105.46% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -357.363% |
| Nascent Biotech, Inc. | -2.08 Million USD | -38.546% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -596.159% |
| Qrons Inc. | -789.34 Thousand USD | -266.429% |
| Rebus Holdings, Inc. | -1.02 Million USD | -183.568% |
| Skye Bioscience, Inc. | -37.64 Million USD | 92.317% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 104.441% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 95.379% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 81.776% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 58.579% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -116.589% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 96.142% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 56.017% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -957.927% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.36% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -58.877% |
| Mesoblast Limited | -87.95 Million USD | 96.712% |
| Marizyme, Inc. | -65.34 Million USD | 95.574% |
| Genus plc | 7.9 Million USD | 136.613% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 73.444% |
| Pharming Group N.V. | -10.54 Million USD | 72.579% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -33.301% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 22.043% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 67.295% |
| ContraFect Corporation | -65.15 Million USD | 95.561% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 40.803% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -67.437% |
| IMV Inc. | -36.48 Million USD | 92.073% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 64.113% |
| MultiCell Technologies, Inc. | -380.07 USD | -760916.129% |
| ONE Bio Corp. | 8.67 Million USD | 133.336% |
| Accustem Sciences Inc. | -3.74 Million USD | 22.796% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 94.405% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -128.263% |
| Q BioMed Inc. | -2.05 Million USD | -40.948% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 22.518% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -21.485% |
| Biomind Labs Inc. | -1.21 Million USD | -138.191% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 95.157% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 6.75% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 63.402% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -48.385% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -19213.528% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 50.279% |
| GB Sciences, Inc. | -1.36 Million USD | -112.414% |
| Alpha Cognition Inc. | -13.77 Million USD | 78.999% |
| HST Global, Inc. | -146.21 Thousand USD | -1878.246% |
| CSL Limited | 2.64 Billion USD | 100.109% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -64.83% |
| Halberd Corporation | -79.67 Thousand USD | -3530.195% |
| Enzolytics Inc. | -2.17 Million USD | -32.872% |
| Agentix Corp. | -1.37 Million USD | -110.477% |
| Resverlogix Corp. | -3.61 Million USD | 19.878% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 8.799% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.02% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3051.422% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 141.77% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 27.199% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 4.42% |
| AVAX Technologies, Inc. | -6.41 Million USD | 54.903% |
| Zenith Capital Corp. | -10.59 Million USD | 72.703% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.971% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -12344.686% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 30.235% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -4685.514% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -44.251% |
| Kadimastem Ltd | -3.3 Million USD | 12.548% |
| Helix BioMedix, Inc. | -1.05 Million USD | -173.886% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 24.263% |
| BioStem Technologies, Inc. | -8.48 Million USD | 65.904% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -555.323% |
| LadRx Corporation | 400.44 Thousand USD | 822.299% |
| Cell Source, Inc. | -5.32 Million USD | 45.644% |
| Regen BioPharma, Inc. | 1.02 Million USD | 382.596% |
| Regen BioPharma, Inc. | 1.02 Million USD | 382.596% |
| NovAccess Global Inc. | -4.76 Million USD | 39.352% |
| Affymax, Inc. | -14.42 Million USD | 79.947% |
| Itoco Inc. | -1.86 Million USD | -54.757% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 34.893% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -73.301% |
| Mobile Lads Corp. | -2.26 Million USD | -27.796% |
| CytoDyn Inc. | -49.84 Million USD | 94.197% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3559.729% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1167.888% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -207.202% |
| SYBLEU INC | -180.3 Thousand USD | -1504.176% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -79.347% |
| International Stem Cell Corporation | -131 Thousand USD | -2107.934% |
| Bioxytran, Inc. | -4.28 Million USD | 32.421% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -5229.441% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -14.313% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.983% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -36.821% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -270.399% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 8.7% |
| Neutra Corp. | -233.46 Thousand USD | -1138.898% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 85.745% |
| PureTech Health plc | -65.69 Million USD | 95.597% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 86.399% |
| IXICO plc | -1.17 Million USD | -145.534% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 70.863% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.937% |
| CSL Limited | 2.64 Billion USD | 100.109% |
| Cellectis S.A. | -103.17 Million USD | 97.197% |